Clinical Trial

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Name: Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma — clinical trial record (NCT05806580)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2023-03-28; most recent amendment 2024-10-21.

Trial Details

NCT Number	NCT05806580
Lead Sponsor	Ruijin Hospital
Conditions	Relapsed or Refractory B-cell Lymphoma
Enrollment	8 participants
Start Date	2023-05-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-10-23